Lilly's Erbitux shows mixed results in cancer studies

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly & Co. and Merck KGaA’s Erbitux failed to help colon cancer patients in a study, which may leave doctors less likely to combine the drug with a certain type of chemotherapy. However, the drug was found to delay the spread of breast cancer by about two months in a study of women with a certain type of aggressive tumor.

Erbitux didn’t slow or delay the progression of colon-cancer tumors and didn’t prolong patients’ lives, according to a study released Sunday at the European Society for Medical Oncology conference in Milan. Patients with a normal version of a gene called KRAS didn’t respond better than those with a mutation.

The results add to a growing body of evidence that Erbitux, known chemically as cetuximab, might not work in certain chemotherapy combinations, said Kjell Magne Tveit, an oncologist at Oslo University Hospital and a researcher on the study. The drug didn’t keep colon cancer at bay in a U.K. trial last year. That trial combined Erbitux with oxaliplatin, the same chemotherapy as in Sunday's study.

“The results from our study and the [U.K.] study together really question whether cetuximab has a clinically significant effect in first line,” Tveit said in a statement.

Erbitux is approved for advanced colon cancer as well as head and neck tumors. Last year, its prescribing information was changed to say the drug won’t help the roughly 40 percent of people whose tumors have the KRAS gene mutation.

“The findings are not consistent with current scientific understanding” of the way Erbitux works, and contradict previous trials, Merck spokeswoman Phyllis Carter said by telephone.

The German drugmaker’s own study, combining Erbitux with a different type of chemotherapy called FOLFIRI, found Erbitux helped normal KRAS patients live an average of 3.5 months longer than those given chemotherapy alone. A second study using a chemotherapy mixture called FOLFOX, which combines oxaliplatin in a different way, also found that Erbitux helped patients, Carter said.

Dubbed NORDIC VII, the trial for which results were released Sunday followed 566 patients from Sweden, Denmark, Norway, Finland and Iceland. Like last year’s U.K. study, the trial was conducted independently from Merck.

However, adding Erbitux to chemotherapy lengthened the time before patients’ cancer progressed from a median 1.5 months to 3.7 months, according to a mid-stage study released Monday at the same European Society for Medical Oncology conference. Twenty percent of Erbitux patients saw their cancer shrink or disappear, versus 10 percent of those on chemotherapy alone.

While Erbitux didn’t provide as large a benefit as researchers had targeted, the results from the 173-patient study show that the drug has “a role in treating breast cancer,” lead researcher Jose Baselga, associate director of the Massachusetts General Hospital Cancer Center in Boston, said in a conference call with reporters.

“The study in my mind is vastly positive,” Baselga said. The results may be grounds for the bigger final-stage studies that would be needed to win regulatory approval for the use of Erbitux against breast cancer, he said.

Monday’s study used a different kind of chemotherapy than that used in the colon-cancer trials.

Merck will make a final decision about whether to pursue more trials of Erbitux in breast cancer after final results from Monday’s study are available, spokeswoman Phyllis Carter said by e-mail.

Lilly, based in Indianapolis, and New York-based Bristol- Myers Squibb Co. market Erbitux in the U.S., while Merck, based in Darmstadt and unrelated to the U.S. drugmaker Merck & Co., sells it elsewhere.


  • Erbitux fails in European colon-cancer study
    Is this worth bringing up with mom's doctor?

Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...